Project CBD: “Is CBD Really Non-Psychoactive?”
If you’re having breast cancer treatment side effects or symptoms that aren’t being controlled, or if you think your doctor isn’t listening to your needs or doesn’t have the experience to give you advice on CBD products, get a second opinion, Weiss suggests. She recommends talking to an oncologist who is knowledgeable about cannabis products if your doctor can’t help.
According to Weiss, some people who use CBD have reported side effects including:
The Future of CBD
Weiss notes that there are all kinds of CBD products beyond oil, such as edibles, capsules, tinctures, creams and oils for skin, and sprays that you can use under your tongue.
What should you look for if you decide to give CBD products a try?
First, let’s break down the terms, which can be confusing.
Mathias Schmucki has also found that talking to other people who currently have or previously had breast cancer is invaluable. A private Facebook group called Fighting Breast Cancer with Cannabis has been helpful in her own journey.
It is also important to note that some studies have shown that CBD might interfere with how your body processes cancer drugs, called a drug interaction. This might make cancer treatments more toxic or make them less effective. More research is needed on these effects, too. For these reasons, always tell your oncologist if you’re thinking about using CBD before you take it.
There is currently 1 CBD treatment approved by the U.S. Food and Drug Administration (FDA) called Epidiolex, which is used to treat a rare and severe form of epilepsy in children. There are not currently any FDA-approved CBD medications for treating cancer or side effects of cancer treatments.
CBD comes from cannabis plants called hemp that are specifically grown with high levels of CBD and low levels of THC. Cannabis plants grown with high levels of THC are usually called marijuana. CBD comes from oil that is extracted from the cannabis plant. That oil can then be ingested as a liquid, a capsule, a gummy, or inhaled through vaping. It can also be added as an ingredient in such products as lotions and skin patches.
Can CBD help people with cancer?
CBD is 1 of the hundreds of chemicals found in the flowering cannabis plant. CBD does not have the psychoactive, or mind-altering, effects of another chemical found in cannabis called tetrahydrocannabinol (THC). THC is the chemical that causes people to experience a “high.” CBD, on the other hand, is being used by some to help ease pain, anxiety, and sleep issues.
To date, no large-scale studies have shown CBD to have benefits for the treatment of people with cancer. Most studies that have been done evaluating CBD as a cancer treatment were in mice or in human cells in the lab. For instance, there are some studies that have shown that CBD inhibits the growth of cancer cells in mice with lung cancer or colon cancer. Another study showed that CBD, together with THC, killed glioblastoma cancer cells in the lab. However, no studies have been conducted in people with cancer.
Cannabidiol, also known as CBD, is one of many chemicals found in the cannabis plant. It has been touted in some online forums as an alternative treatment, and even a cure, for many illnesses, including cancer. And, some people with cancer say that CBD has helped them as a complementary therapy in managing their symptoms and side effects from standard cancer treatment.
There are 2 synthetic cannabis medications, nabilone (Cesamet) and dronabinol (Marinol or Syndros), that are FDA-approved to treat nausea and vomiting related to chemotherapy. These medications are made in a laboratory.
This is a 6-week randomized, double-blind, placebo-controlled, parallel group design trial followed by an open-label extension phase of 12 weeks, to evaluate tolerability of medical cannabis oil to reduce chronic pain intensity.
Consecutive adult patients between the ages of 18 and 75, male and female, with cancer pain, with an average weekly pain intensity score greater than 4 on the 11 points Numerical Rate Scale (NRS), will be prospectively recruited and invited to participate in this trial.
At the end of the first phase of the study, patients who wish to participate in the open-label extension phase will have the option to continue in the same treatment regimen. For the placebo group, patients will have the option to receive the active treatment during the 12-week open-label phase if the study physician feels it may potentially provide benefits. Similarly, the dose will be titrated up in the placebo group who wants to receive the active drug in the extension program.
Informed consent will be obtained by a Research Assistant.
Follow-up visits either in person or by phone will be at 1 week, 3 weeks and 6 weeks of treatment.